Catheter Precision, Inc. (NYSE: VTAK)

Catheter Precision, Inc., also known as VTAK, is a medical technology company that specializes in the development and commercialization of innovative medical devices for the treatment of cardiac arrhythmias. The company's primary product is the VIVO System, a non-invasive imaging system that uses 3D cardiac mapping to help diagnose and treat ventricular arrhythmias.

The VIVO System is a cutting-edge technology that provides electrophysiologists with a more accurate and efficient way to diagnose and treat ventricular arrhythmias, which are a type of abnormal heart rhythm that can be life-threatening if left untreated. The system uses a combination of 3D imaging and proprietary algorithms to create a detailed map of the heart, allowing physicians to identify the source of the arrhythmia and develop a treatment plan. The VIVO System has been used in over 1,000 procedures and has achieved CE Mark approval, allowing it to be commercialized in the European Union. The company is also seeking FDA 510(k) clearance in the United States.

In addition to the VIVO System, Catheter Precision is also developing the LockeT device, a suture retention device that is designed to aid in wound healing and reduce the risk of complications after cardiac surgery. The LockeT device has been registered with the FDA and is classified as a Class I product, which means it is subject to general controls and does not require clinical data or a formal submission process.

The company operates in a highly competitive market, with large medical device companies such as Medtronic, Abbott Laboratories, and Boston Scientific Corp. also developing and marketing products for the treatment of cardiac arrhythmias. However, Catheter Precision believes that its innovative technology and focus on non-invasive imaging will allow it to differentiate itself from its competitors and capture a significant share of the market.

The company's primary customers are hospitals providing cardiac electrophysiology lab procedures. Catheter Precision believes that there are 2,000 to 3,000 EP labs in the U.S. and a similar number of labs outside of the U.S. performing approximately 600,000 ablation procedures annually. The company uses a mix of distribution partners, independent sales agents, and direct employees to sell its products. In the U.S., the VIVO System and patches are currently sold by direct employees and independent sales agents who call on electrophysiologists, lab staff, and hospital administrators. In Europe, the company's products are sold through distributors, supported by three full-time contracted employees.

Catheter Precision has also entered into a co-marketing agreement with Stereotaxis, a company that develops and markets robotic systems for use in electrophysiology procedures. The agreement allows Stereotaxis to promote the VIVO System to its customers, and in return, Stereotaxis receives a payment equal to 45% of the revenue generated from VIVO sales at hospitals that use Stereotaxis' robotic systems.

The company's major focus is on leveraging its existing technology platform for new applications and improvements to its existing applications. Future research and development efforts will involve continued enhancements to and cost reductions for VIVO and LockeT. The company will also explore the development of other products that can be derived from its core technology platform and intellectual property.

The company is subject to extensive regulation by the Food and Drug Administration (FDA) and other federal and state statutes and regulations. The FDA regulates the design, manufacture, storage, record-keeping, approval, labeling, promotion, post-approval monitoring and reporting, distribution and import and export of medical devices. The company must comply with the FDA's regulations and guidelines for the development, testing, and marketing of its products.